Compare FLWS & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLWS | DTIL |
|---|---|---|
| Founded | 1976 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.5M | 194.3M |
| IPO Year | 1999 | 2019 |
| Metric | FLWS | DTIL |
|---|---|---|
| Price | $3.94 | $7.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $45.00 |
| AVG Volume (30 Days) | ★ 775.2K | 242.1K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $1,151,921,000.00 | $1,070,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.52 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.89 | $3.53 |
| 52 Week High | $8.44 | $8.82 |
| Indicator | FLWS | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 59.77 | 68.62 |
| Support Level | $3.03 | $4.50 |
| Resistance Level | $4.77 | $8.82 |
| Average True Range (ATR) | 0.37 | 0.52 |
| MACD | 0.11 | 0.07 |
| Stochastic Oscillator | 41.30 | 91.50 |
1-800-Flowers.com Inc is a provider of gifts designed to help customers express, connect, and celebrate. The company's e-commerce business platform features all brands, including 1-800-Flowers.com, 1-800-Baskets.com, Cheryl's Cookies, Harry and David, PersonalizationMall.com, Shari's Berries, FruitBouquets.com, Moose Munch, The Popcorn Factory, Wolferman's Bakery, Stock Yards, and Simply Chocolate. The company's business segments are; Consumer Floral and Gifts, BloomNet, and Gourmet Foods & Gift Baskets. The maximum revenue for the company is generated from its Gourmet Foods & Gift Baskets segment.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).